Q-omics provides the consensus-scored ANKRD9 profile across patient tissues and cancer cell-line models. ANKRD9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ANKRD9 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ANKRD9 RNA expression shows 18,894 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where ANKRD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD9 survival associations across molecular data types. ANKRD9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD9 RNA expression–survival associations across cancer types. High ANKRD9 expression shows unfavorable associations in ACC, SKCM, THCA, LUAD and LIHC, but favorable associations in KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ANKRD9 RNA expression.
This table summarizes ANKRD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD9 shows lower tumor expression in THCA, KIRC, COAD and KIRP and higher tumor expression in LIHC and UCEC. The THCA box plot shows higher ANKRD9 RNA expression in normal versus tumor tissue (log2 FC = −2.202, t-test p < 0.001).
This table shows molecular features associated with ANKRD9 in patient tissues and cancer cell lines. In patient samples, ANKRD9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
